- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top Biosimilars Interviews of 2017
2017 brought a number of notable guests to The Center for Biosimilars®. Here are the most-watched interviews of the year.
2017 brought a number of notable guests to The Center for Biosimilars®. Below are the most-watched interviews of the year:
Number 5: Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.
Number 4: Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the importance of pharmacist education on biosimilar treatments.
Number 3: Joseph Fuhr, PhD, explains why biosimilars could bring on brand-to-brand competition.
Number 2: Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.
Number 1: Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses incentives for biosimilar applicants to engage in the BPCIA "patent dance" after the Supreme Court's ruling in Sandoz v Amgen.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
